Pfizer, ADCs and Summit

Pfizer sets sights on Summit’s bispecific in combo with its ADCs
Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially landscape-changing combinations.”
Summit Therapeutics to test lead cancer drug with Pfizer ADCs
Summit Therapeutics (NASDAQ:SMMT) has entered a clinical trial collaboration to evaluate its cancer drug, ivonescimab, in combination with Pfizer (NYSE:PFE) antibody drug conjugates across multiple solid tumor settings.
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit Therapeutics shares rise on Pfizer trial collaboration
Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the development of ivonescimab, particularly in non-small cell lung cancer and other solid tumors. They emphasized the importance of novel mechanisms in making a significant impact for cancer patients and physicians.
Summit Therapeutics jumps 5% to $23.19 after trial pact with Pfizer
EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE)Discover the Best Stocks and Maximize Your Portfolio:
Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.
Summit Therapeutics announces clinical trial collaboration with Pfizer
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials
Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug ...
FierceBiotech6h
Pfizer to test Summit’s white-hot bispecific with ADCs
Ivonescimab remains the frontrunner, with Summit on track to report topline data from a phase 3 non-small cell lung cancer ...
Investopedia on MSN4h
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss
Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...
ENDPOINTS NEWS7h
Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos
With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...
Summit Therapeutics Shares Down as 4Q Loss Widens
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...